Australian Patent Office accepts bioAffinity Technologies' patent application for its platform technology to assess lung health and predict disease.

To combine TruCytes Biomarker Controls with the Cell Q platform to enhance quality and automation.

Analytical and process development (PD/AD) strategies directly impact how quickly and reliably cell therapies reach patients.

Slingshot Biosciences, the leader in precision-engineered cell mimic controls, announced a strategic collaboration with Cellares, the first Integrated Development and Manufacturing Organization (IDMO) ...

How KFSHRC's Advanced Hematology Laboratory Is Transforming Diagnostics Across The Middle East. EINPresswire / -- At King Faisal Specialist Hospital and Research Centre (KFSHRC), hematology ...

Affinity Technologies, Inc. ( ($BIAF) ) has issued an update. On October 16, 2025, bioAffinity Technologies, Inc. announced it received a ...

The UW Carbone Cancer Center and UW Biotechnology Center hosted the 8th annual BadgerConnect Research Services Fair Oct. 2 at ...

Fibrosis occurs when inflammation activates immune cells and fibroblasts to release collagen and cytokines that remodel and ...

(A) The Incucyte® Apoptosis Assay allows automated imaging and quantitative analysis of every well of a 96/384-well plate, ...

A review of machine learning (ML) models developed to support the management of chronic lymphocytic leukemia (CLL) have demonstrated positive outcomes, including accurate diagnosis and improved work ...

Investing.com -- bioAffinity Technologies Inc (NASDAQ:BIAF) stock surged 14% on Thursday after the biotechnology company announced it received a notification of allowance from the United States Patent ...

Affinity Technologies' stock surged after a patent notice and Nasdaq compliance update but slipped in after-hours trading.